antibodies against alk1  (R&D Systems)

Journal: Frontiers in Immunology

Article Title: Potential Targets to Mitigate Trauma- or Sepsis-Induced Immune Suppression

doi: 10.3389/fimmu.2021.622601

Figure Lengend Snippet: Clinical Trials targeting TGF-ß or its receptor.

Article Snippet: , PF-03446962 , Pfizer , Monoclonal antibody against Activin Receptor-Like Kinase-1 (ALK1), a type I subclass of the TGFβ receptor , Advanced solid tumors , Phase 1 NCT00557856.

Techniques: Clinical Proteomics, Modification, Cream, Blocking Assay, Activation Assay

Journal: Frontiers in Cellular Neuroscience

Article Title: Activin Receptor-Like Kinase 1 Combined With VEGF-A Affects Migration and Proliferation of Endothelial Cells From Sporadic Human Cerebral AVMs

doi: 10.3389/fncel.2018.00525

Figure Lengend Snippet: mRNA expression of gene Alk1 in HA-ECs and cAVM-ECs in patients with different ages. Levels of VEGF-A mRNA expression (0.986 ± 0.134) in the HA-ECs were lower than that in cAVM-ECs (8 years) (4.183 ± 0.238) and cAVM-ECs (14 years) (3.834 ± 0.451) (all ∗ p < 0.05). In addition, the levels of VEGF-A mRNA expression were (2.92 ± 0.58) in cAVM-ECs (17 years), (3.04 ± 0.79) in cAVM-ECs (29 years), (3.08 ± 0.37) in cAVM-ECs (32 years), (2.08 ± 0.28) in cAVM-ECs (42 years), (1.97 ± 0.24) in cAVM-ECs (44 years), and (1.97 ± 0.25) in cAVM-ECs (51 years), all of that were higher than that (0.986 ± 0.134) in HA-ECs (all ∗ p < 0.05).

Article Snippet: After blocking with 5% non-fat dried milk for 2 h at RT, membranes were incubated with the primary antibodies overnight at 4°C: Primary antibodies against Alk1 (1:1,000, Cell Signaling Technology, Cat No. 31278, United States) and GAPDH (1:5,000, Cell Signaling Technology, Cat No. 51332, United States), each primary antibody was diluted in blocking buffer and then incubated overnight at 4°C.

Techniques: Expressing

Journal: Frontiers in Cellular Neuroscience

Article Title: Activin Receptor-Like Kinase 1 Combined With VEGF-A Affects Migration and Proliferation of Endothelial Cells From Sporadic Human Cerebral AVMs

doi: 10.3389/fncel.2018.00525

Figure Lengend Snippet: Expression of Alk1 proteins in HA-ECs and cAVM-ECs. (A–D) Immunofluorescent staining to detect the Alk1 protein expressed in HA-ECs and cAVM-ECs. (A–C) In HA-ECs, (A) Alk1 protein was stained by Green fluorescent, (B) nuclei was stained by DAPI in Green fluorescent; (C) merge; (D–F) In cAVM-ECs, (D) Alk1 protein was stained by Green fluorescent, (E) nuclei was stained by DAPI in Green fluorescent; the fluorescence intensity in cAVM-ECs was obviously lower than in HA-ECs; (F) merge. Scale bar = 200 μm; (G) Detect the expression of Alk1 by Western blot, (H) expression of Alk1 proteins in the HA-ECs cultures were significantly higher than that in cAVM-ECs in vitro ( ∗ p < 0.05).

Article Snippet: After blocking with 5% non-fat dried milk for 2 h at RT, membranes were incubated with the primary antibodies overnight at 4°C: Primary antibodies against Alk1 (1:1,000, Cell Signaling Technology, Cat No. 31278, United States) and GAPDH (1:5,000, Cell Signaling Technology, Cat No. 51332, United States), each primary antibody was diluted in blocking buffer and then incubated overnight at 4°C.

Techniques: Expressing, Staining, Fluorescence, Western Blot, In Vitro